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http://dx.doi.org/10.1016/j.jfma.201Background/Purpose: Topical 5-aminolevulinic acid-mediated photodynamic therapy (ALA-
PDT) is effective for treatment of oral precancerous and cancerous lesions. This in vitro study
tried to examine whether the SCC4 cell killing by ALA-PDT was enhanced by pretreatment of
methotrexate (MTX).
Methods: To measure the SCC4 cell killing abilities by MTX-pretreated ALA-PDT (MTXeALA-
PDT), the SCC4 cells were pretreated with 0 mg/L, 0.001 mg/L, 0.01 mg/L, 0.1 mg/L, or
1 mg/L of MTX for 72 hours, then incubated with 0 mM, 0.0625 mM, 0.125 mM, 0.187 mM,
0.25 mM, or 0.375 mM ALA for 4 hours, and subsequently illuminated with a 640-nm light-
emitting diode array at a light dose of 10 J/cm2. The 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide assay was conducted at 24 hours to quantify SCC4 cell sur-
vival rates after MTXeALA-PDT treatment. Western blot analyses were used to examine the
MTX-mediated enhancement in the expressions of the heme production-related enzymes,have no conflicts of interest relevant to this article.
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MTXeALA-PDT for SCC4 cells 89coproporphyrinogen oxidase (CPOX), protoporphyrinogen oxidase (PPOX), and ferrochelatase,
in the MTX-preconditioned SCC4 cells.
Results: Pretreatment of SCC4 cells by 0.001 mg/L MTX for 72 hours resulted in a significant
augmentation in MTXeALA-PDT-induced killing of SCC4 cells (p < 0.05). The SCC4 cells treated
with 0.001 mg/L MTX for 72 hours showed a significant and 1.65-fold increase in CPOX expres-
sion compared with the control SCC4 cells without MTX treatment (p < 0.05). However, no sig-
nificant changes in the expressions of PPOX and ferrochelatase were observed in the SCC4 cells
pretreated with different concentrations of MTX.
Conclusion: MTX enhances ALA-PDT-induced SCC4 cell killing through upregulation of CPOX
expression and subsequent increase in intracellular protoporphyrin IX production in SCC4 cells.
Copyright ª 2014, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.Introduction
Oral squamous cell carcinoma is the sixth most common
cancer in the world.1 Oral cancer is also the sixth most
frequent cancer in Taiwan.2 Because of the continuously
increased prevalence of oral cancer and poor survival for
patients with advanced oral cancers, it is very important to
find an effective treatment modality for oral cancer.3
Traditional treatment for oral precancers and cancers is
total surgical excision that always leads to scar formation for
a large precancerous or cancerous lesion.4e6 Photodynamic
therapy (PDT) is another effective treatment option for
human precancerous and cancerous lesions because it is
noninvasive, is well tolerated by patients, can be used
repeatedly without cumulative side effects, and results in
little scar formation.7 5-Aminolevulinic acid (ALA) itself is
not a photosensitizer but serves as the biological precursor of
the photosensitizer, protoporphyrin IX (PpIX), in the heme
biosynthesis pathway. When ALA is topically applied on the
oral lesions or systemically administrated by the patients, it
will be absorbed by the lesional epithelial cells and results in
accumulation of a relatively high concentration of PpIX in
these cells.8e12 ALA is superior to other photosensitizers
because it can be rapidly cleared from the tissues and the
body within 48 hours and patients after ALA-PDT treatment
have no problem of prolonged skin photosensitivity.7e12
PDT involves two individual nontoxic components,
namely, light and photosensitizer. When a photosensitizer
in tissues is activated by a light of specific wavelength, it
transfers energy from light to molecular oxygen, resulting
in the generation of reactive oxygen species (ROS).7 There
are three main mechanisms by which PDT mediates tumor
destruction. First, the ROS can kill tumor cells directly.
Second, PDT can damage the tumor-associated vasculature,
leading to thrombus formation and subsequent tumor
infarction. Third, PDT can also activate an immune
response against tumor cells.7
Previous studies have shown that ALA-PDT is effective
for the treatment of both oral cancer and precancers.9e22
However, for relatively large oral precancerous lesions,
four to six topical ALA-PDT treatments are needed to ach-
ieve a complete regression of the lesion.17e22 Previous
studies found that pretreatment of prostate cancer cells
and skin keratinocytes or carcinoma cells with a low-dose
methotrexate (MTX) can have a two- to fourfold upregula-
tion of expression of coproporphyrinogen oxidase (CPOX)
proteins, resulting in a two- to fourfold increase in intra-
cellular PpIX production and subsequent killing of theseepithelial or cancer cells after exposure to the light.23e28
Therefore, we hypothesize that when oral cancer cells
are pretreated with a nontoxic and low dose of MTX and
then treated with ALA-PDT, the PDT efficacy can be
augmented through upregulation of CPOX expression and
subsequent increase in PpIX production in oral cancer cells.
In this study, we used human SCC4 cell line to measure the
SCC4 cell killing abilities by MTX-pretreated ALA-PDT
(MTXeALA-PDT). The SCC4 cells were pretreated with
0e1 mg/L of MTX for 72 hours, then incubated with
0e0.375 mM ALA for 4 hours, and subsequently illuminated
with a 640-nm light-emitting diode (LED) array at a light
dose of 10 J/cm2. The 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay was performed
at 24 hours to quantify SCC4 cell survival rates after
MTXeALA-PDT treatment. Western blot analyses were used
to examine the MTX-mediated enhancement in the ex-
pressions of CPOX, protoporphyrinogen oxidase (PPOX), and
ferrochelatase in the MTX-pretreated SCC4 cells.
Materials and methods
In vitro survival assays
An in vitro study was carried out to examine the roles of MTX
in the MTXeALA-PDT-induced killing of human SCC4 cells.
The SCC4 cells were purchased from Bioresource Collection
and Research Center (Hsinchu, Taiwan) and cultured at 37 C
in a humidified CO2 incubator in Dulbecco’s Modified Eagle
Medium/F12 medium (Invitrogen, Grand Island, NY, USA)
supplemented with 10% fetal bovine serum (Invitrogen). The
SCC4 cells were plated in 24-well plates at a cell number of
1  104 (the control group) or 4  104 (the MTXeALA-PDT
group) and pretreated with the MTX (SigmaeAldrich Corp.,
St. Louis, MO, USA) at the concentration of 0 mg/L,
0.001mg/L, 0.01mg/L, 0.1mg/L, or 1mg/L for 72 hours. The
SCC4 cells were then incubated with 0 mM, 0.0625 mM,
0.125 mM, 0.187 mM, 0.25 mM, or 0.375 mM ALA for 4 hours,
and susequently exposed to a self-made 640-nm LED array at
a light dose of 10 J/cm2. The MTT assay was conducted at 24
hours to quantify the cell survival rate.
Western blot analyses for key enzymes for PpIX
synthesis in SCC4 cells
The SCC4 cells were treated with 0 mg/L, 0.001 mg/L,
0.01 mg/L, 0.1 mg/L, or 1 mg/L MTX for 72 hours and then
90 D.-F. Yang et al.lysed in the lysis buffer (PRO-PREP protein extraction so-
lution; Intron Biotechnology Inc., Seoul, Korea). Samples
containing an equal quantity of protein, as determined by
bicinchoninic acid protein assay (Thermo Fisher Scientific
Inc., Rockford, IL, USA), were denatured in sample buffer for
10 minutes at 100 C and resolved on a 4e12% Bis-Tris
acrylamide gel along with molecular-size markers. Electro-
phoresiswas carried out at a constant voltage (200 V) at room
temperature. Proteins were electrophoretically transferred
to a nitrocellulose membrane (Whatman GmbH, Dassel,
Germany) at a constant voltage (100 V) for 5 hours at 4 C.
The blot was then blocked with 10% caseinephosphate-
buffered saline, incubated with rabbit primary antibodies
against CPOX (GenTex, Taipei, Taiwan) at the dilution of
1:1000, PPOX (Abnova, Taipei, Taiwan) at the dilution of
1:500, ferrochelatase (GenTex) at the dilution of 1:1000, and
glyceraldehyde 3-phosphate dehydrogenase (GAPDH; Gen-
Tex) at the dilution of 1:1000, followed by peroxidase-
conjugated goat antirabbit immunoglobulin G (GenTex) at
the dilution of 1:5000, and then developed in enhanced
chemiluminescence substrate (PerkinElmer, Boston, MA,
USA). Intensities of hybridized protein bands on Western
blots were semiquantified by VisionWorkers LS software
(UVP, LLC, Upland, CA, USA). Blots were scanned using the
BioDoc-It 220 imaging system (UVP, Upland, CA, USA).LED light source
An LED array light was used for the in vitro cell study. The
peak of LED light source is 640 nm, and full width and half
maximum is 20 nm. The power density of the LED light
system was 64 mW/cm2 and the period of light treatment
was set at 159 seconds to deliver a light dose of 10 J/cm2.Statistical analysis
Duncan test was used to compare the SCC4 cell survival
rates after MTXeALA-PDT treatments between any two of
the five groups treated with different concentrations of
MTX at a fixed ALA concentration. Student t test was used
to compare the mean CPOX, PPOX, and ferochelatase
enzyme expression levels in SCC4 cells between any two of
the five groups pretreated with five different concentra-
tions of MTX.Results
MTX enhances ALA-PDT-induced killing of human
SCC4 cells
The cell killing experiments showed that, in SCC4 cells
pretreated with 0 mg/L, 0.001 mg/L, 0.01 mg/L, 0.1 mg/L,
or 1 mg/L MTX for 72 hours, the ALA-PDT-induced killing of
SCC4 cells increased in an ALA dose-dependent manner
(Table 1 and Fig. 1). The cell killing abilities by MTXeALA-
PDT when using 0.001 mg/L MTX and 0.0625 mM, 0.125 mM,
or 0.187 mM ALA were significantly greater (p < 0.05 based
on the Duncan test) than the corresponding data of the
control group without MTX pretreatment and of otherexperimental groups pretreated with 0.01 mg/L, 0.1 mg/L,
or 1 mg/L MTX for 72 hours.
MTX-induced CPOX protein expression in SCC4 cells
To investigate the biochemical mechanisms underlying the
MTX-mediated enhancement of ALA-PDT-induced killing of
SCC4 cells, we evaluated changes in the expression of en-
zymes involved in the PpIX synthesis in SCC4 cells pre-
treated with different concentrations of MTX for 72 hours.
Western blotting was performed to evaluate the expression
levels of the CPOX (40 kDa), PPOX (26 kDa), ferrochelatase
(48 kDa), and GAPDH (36 kDa, control) proteins. The
semiquantitative Western blotting analyses showed a sig-
nificant increase (1.65-fold higher than the control level) in
the level of CPOX expression in the SCC4 cells pretreated
with 0.001 mg/L MTX, compared with corresponding levels
in SCC4 cells pretreated with 0 mg/L (control), 0.01 mg/L,
0.1 mg/L, or 1 mg/L MTX, respectively (p < 0.05; Fig. 2).
However, no significant changes in the expression of PPOX,
ferrochelatase, and GAPDH proteins were observed in the
SCC4 cells pretreated with five different concentrations of
MTX for 72 hours.
Discussion
This study found that the SCC4 cells pretreated with
0.001 mg/L MTX for 72 hours showed a significant and 1.65-
fold augmentation in the CPOX expression, compared with
the CPOX expression in the control SCC4 cells without MTX
treatment. The significant increase in CPOX protein
expression can lead to an increase in intracellular PpIX
production in SCC4 cells that in turn augments MTXeALA-
PDT-induced killing of SCC4 cells after PDT treatment.
However, no significant changes in the expressions of PPOX
and ferrochelatase were observed in the SCC4 cells pre-
treated with different concentrations of MTX. These find-
ings indicate that MTX-induced increase in the CPOX
expression in SCC4 cells is the main mechanism responsible
for an augmented MTXeALA-PDT-induced killing of SCC4
cells.
The efficacy of ALA-PDT depends on the amount of PpIX
accumulated in the lesional epithelial or cancer cells. PpIX
is the seventh product in the heme biosynthesis pathway.
The increase in the expression of CPOX (the enzyme that is
responsible for the sixth step in heme production, con-
verting coproporphyrinogen III into protoporphyrinogen IX)
and the decrease in the expression of ferrochelatase (the
enzyme that catalyzes the terminal or eighth step in the
biosynthesis of heme, catalyzing the insertion of Fe2þ into
PpIX to form heme) are responsible for the increased
accumulation of PpIX in lesional epithelial or cancer
cells.29,30 Previous studies have shown that the agents
capable of inducing cellular differentiation can also cause
an elevation in the level of PpIX in prostate cancer cells and
skin epithelial cells.23e28 Because MTX can promote dif-
ferentiation and PpIX accumulation in carcinoma cells, MTX
may serve as a drug to augment the efficacy of ALA-PDT for
tumor cell killing. Sinha et al25 studied the MTX-pretreated
ALA-PDT for the killing of prostate cancer cells. They found
that prostate cancer cells pretreated by MTX and followed
Table 1 Cell survival rates of SCC4 cells pretreated with methotrexate (MTX) at five different concentrations for 72 hours,
then treated with ALA at five different concentrations for 4 hours, and subsequently illuminated with an LED array at a light dose
of 10 J/cm2.
MTX level (mg/L) ALA concentration (mM)
0.0625* 0.125* 0.187* 0.25* 0.375
0 98.2  1.5** 83.6  1.3** 75.7  3.3** 61.7  2.7** 49.7  7.9**
0.001 84.6  6.2*** 74.5  1.2*** 65.1  1.0*** 54.0  7.2** 40.3  1.6**
0.01 98.9  0.6** 95.5  5.3** 89.0  3.0** 78.9  10.4** 66.8  15.0**
0.1 95.8  0.5** 96.9  1.3** 90.2  3.7** 78.2  08.1** 64.5  17.1**
1 101.5  3.3** 96.5  3.7** 81.3  7.4** 66.7  14.9** 50.5  22.0**
*Duncan test was used to compare the cell survival rates of SCC4 cells after MTXeALA-PDT treatments between any two of the five
groups pretreated with five different concentrations of MTX at a fixed ALA concentration. Groups with different asterisks (**,***) indicate
a significant difference between the two groups with p < 0.05. Moreover, groups with ‘**’ indicate no significant difference between the
two groups.
ALA Z 5-aminolevulinic acid; LED Z light-emitting diode; PDT Z photodynamic therapy.
MTXeALA-PDT for SCC4 cells 91by ALA incubation can result in a threefold increase in
intracellular PpIX level. The threefold increase in PpIX level
in prostate cancer cells is due to the threefold augmenta-
tion in expression of CPOX induced by MTX. Transfection of
prostate cancer cells with a CPOX-expressing vector also
stimulates the accumulation of PpIX in cells. In addition,
after exposure to 512-nm light, killing is significantly
enhanced in MTX-preconditioned cells. These findings sug-
gest that MTX, when used to modulate intracellular pro-
duction of endogenous PpIX, may provide a new
combination PDT approach for certain cancers.25 Previous
studies also demonstrated that low-dose MTX can enhance
ALA-PDT in skin carcinoma cells in vitro and in vivo.26e28
MTX preconditioning of monolayer cultures canFigure 1 Cell survival rates of SCC4 cells after MTXeALA-
PDT. The SCC4 cells were treated with 0 mg/L (control),
0.001 mg/L, 0.01 mg/L, 0.1 mg/L, or 1 mg/L MTX for 72 hours,
then incubated with 0 mM, 0.0625 mM, 0.125 mM, 0.187 mM,
0.25 mM, or 0.375 mM ALA for 4 hours, and subsequently illu-
minated with a self-made 640-nm LED array at a light dose of
10 J/cm2. * The mean cell survival rates of SCC4 cells after
MTXeALA-PDT treatments were compared by Duncan test be-
tween any two of the five groups pretreated with five different
concentrations of MTX at a fixed ALA concentration with
p < 0.05. ALA Z 5-aminolevulinic acid; LED Z light-emitting
diode; MTX Z methotrexate; PDT Z photodynamic therapy.preferentially augment intracellular PpIX levels two- to
fourfold in skin carcinoma cells versus normal keratino-
cytes. Photodynamic killing is synergistically enhanced by
the MTX-combined therapy compared with PDT alone. MTX
enhancement of PpIX levels is achieved over a broad MTX
concentration range (0.0003e1.0 mg/L). PpIX enhancement
correlates with a fourfold increase in expression of CPOX
and no change or a slight decrease in expression of ferro-
chelatase. MTX preconditioning also enhances PpIX accu-
mulation in organotypic cultures of immortalized
keratinocytes, chemically induced skin tumors in mice, and
human A431 squamous cell tumors implanted subcutane-
ously in mice.26 The findings of the aforementioned studies
and the present study indicate that different carcinoma
cells may have different responses of the expression of
CPOX and ferrochelatase after pretreatment with the same
concentration of MTX for the same period.23e28 Neverthe-
less, the nontoxic and low dose of MTX pretreatment for 3
days is an effective method to increase intracellular PpIX
production in carcinoma cells; this in turn may augment the
efficacy of ALA-PDT on different carcinoma cells.
In conclusion, MTX enhances ALA-PDT-induced SCC4 cell
killing through the upregulation of CPOX expression and
subsequent increase in intracellular PpIX production in
SCC4 cells. In addition to MTX, vitamin D is also a useful
biological enhancer of ALA-PDT.31,32 Sato et al31 found that
vitamin D enhances ALA-mediated PpIX production and
photodynamic cell death in three-dimensional organotypic
cultures of keratinocytes. Anand et al32 also showed that
vitamin D3 can raise tumoral accumulation of the PpIX up to
10-fold, mainly due to the augmentation of CPOX expres-
sion and the reduction of ferrochelatase expression in
tumor cells. Moreover, very low doses of vitamin D3
(0.1e1 mg/kg body weight) are sufficient to elicit tumor-
selective enhancement to ALA-PDT efficacy. Cryotherapy
can also be used prior to topical ALA-PDT at the same visit
to facilitate the diffusion of ALA into the precancerous and
cancerous epithelial cells to improve the clinical outcome
of topical ALA-PDT.33 Mi et al34 used the combination
therapy of cryotherapy plus topical ALA-PDT and cryo-
therapy alone to treat 80 patients with multiple condylo-
mata acuminata. They found that the combination therapy
of cryotherapy followed by topical ALA-PDT can achieve a
Figure 2 Western blot analyses of the expressions of the
CPOX, PPOX, and ferrochelatase proteins in SCC4 cells treated
with different concentrations of MTX. The expressions of CPOX,
PPOX, ferrochelatase (FECH), and glyceraldehyde 3-phosphate
dehydrogenase (GAPDH; control) proteins were semi-
quantitatively evaluated in SCC4 cells pretreated with 0 mg/L
(control), 0.001 mg/L, 0.01 mg/L, 0.1 mg/L, and 1 mg/L MTX
for 72 hours. Each Western blot was performed using anti-
bodies against CPOX, PPOX, FECH, or GAPDH. The expression of
CPOX in the SCC4 cells treated with 0.001 mg/L MTX for 72
hours increased 1.65-fold, compared with that in the control
SCC4 cells without MTX treatment. * Student t test was used to
compare the mean CPOX, PPOX, or FECH enzyme expression
levels in SCC4 cells between any two of the five groups pre-
treated with five different concentrations of MTX with
p < 0.05. CPOX Z coproporphyrinogen oxidase;
FECHZ ferrochelatase; GAPDHZ glyceraldehyde 3-phosphate
dehydrogenase; MTX Z methotrexate; PPOX Z
protoporphyrinogen oxidase.
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than the cryotherapy alone for the treatment of multiple
condylomata acuminata. Combination therapy of topical
ALA-PDT followed by cryotherapy is also effective for the
treatment of a large oral verrucous hyperplasia lesion.35
The findings of the aforementioned studies indicate that
MTX- or vitamin D-pretreated ALA-PDT and combination
therapy of cryotherapy plus ALA-PDT are effective treat-
ment modalities for precancerous and cancerous lesions. In
addition, better clinical outcomes may be achieved, when
oral lichen planus is treated by combination therapy of
MTX- or vitamin D-pretreated topical ALA-PDT plus systemicadministration and local application or injection of
steroid.36e38 Further human clinical trials are needed to
evaluate the efficacy of the combination therapy of drug
pretreatment or cryotherapy plus ALA-PDT on oral pre-
cancers or cancers.
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